Background: The incidence of obesity is increasing worldwide. Recent evidence shows that the incidence of Crohn's disease (CD) is increasing as well. Adipocytes release a variety of proinflammatory cytokines and peptides. Visceral adiposity may play an important role in the initiation and perpetuation of inflammation in CD. We report on an analysis of body weight in CD clinical trials between 1991 and 2008.
Methods: MEDLINE-based databases were searched for randomized controlled trials pertaining to CD. A time-trend analysis was carried out to investigate changes in weight and disease activity over time. Potential correlation between subject weight and clinical activity was studied.
Results: Forty randomized controlled trials involving a total of 10,282 patients with CD conducted between 1991 and 2008 were included. No significant change in gender distribution was noted throughout the follow-up. A significant increase in weight (r2 = 0.360; 95% confidence interval [CI]: 0.4556–0.8813) and body mass index (r2 = 0.1431; 95% CI: 0.02628–0.2272) was observed over the time period. Study subjects demonstrated a significant increase in clinical disease activity as measured by the Crohn's disease activity index (r2 = 0.1092; 95% CI: 2.101–9.087) and disease duration (r2 = 0.06340; 95% CI: 0.02421–0.2530) over the same time period.
Conclusions: We demonstrate increasing body weight over time from 1991 to 2008 in CD as evidenced by baseline data from randomized clinical trials. Adiposity may play a potential role in initiating and perpetuating intestinal inflammation, a hypothesis that should be explored further.
Article first published online 13 August 2013
Department of Medicine, Inflammatory Bowel Disease Clinic and Alberta IBD Consortium, University of Calgary, Calgary, AB, Canada.
Reprints: Subrata Ghosh, MD, Department of Medicine, University of Calgary, Alberta Health Services, Calgary Zone, Room 930, North Tower, Foothills Medical Centre, 1403, 29th St. NW, Calgary, AB T2N 2T9, Canada (e-mail: email@example.com).
Supported by Alberta Innovates Health Solutions (AIHS) and the Snyder Institute for Chronic Diseases.
The authors have no conflicts of interest to disclose.
Received March 26, 2013
Accepted April 27, 2013